Conexiant’s news site is now MDSpire News. Learn more
Advertisement
FDA adds generic valganciclovir oral solution
The new option is indicated for CMV prophylaxis in pediatric kidney and heart transplant recipients, as well as adult CMV retinitis and transplant prophylaxis.
Clinical Scorecard: FDA adds generic valganciclovir oral solution
At a Glance
Category
Detail
Condition
Cytomegalovirus (CMV) infection, including CMV retinitis and CMV disease in transplant recipients
Key Mechanisms
Valganciclovir is an antiviral indicated for CMV retinitis treatment in adults with AIDS and CMV disease prevention in specified high-risk transplant recipients.
Target Population
Adults with AIDS and high-risk kidney, heart, or kidney-pancreas transplant recipients; reference-product labeling also includes pediatric kidney and heart transplant recipients.
Care Setting
Prescription treatment and prophylaxis; the oral solution must be prepared by a pharmacist before dispensing.
Key Highlights
FDA granted final approval to a generic valganciclovir oral solution, 50 mg/mL, through the abbreviated new drug application pathway.
The generic is therapeutically equivalent to Valcyte for Oral Solution, the reference-listed product.
The approval announcement reported no new clinical efficacy or safety findings.
Valganciclovir carries boxed warnings for hematologic toxicity, impaired fertility, fetal toxicity, mutagenesis, and carcinogenesis.
Guideline-Based Recommendations
Diagnosis
Management
Valganciclovir is indicated for CMV retinitis treatment in adults with AIDS and CMV disease prevention in high-risk kidney, heart, and kidney-pancreas transplant recipients.
Reference-product labeling includes prophylaxis for pediatric kidney transplant recipients aged 4 months to 16 years and heart transplant recipients aged 1 month to 16 years.
Administer the oral solution with food; a pharmacist must prepare it before dispensing.
Adults should use valganciclovir tablets rather than oral solution unless they are unable to swallow tablets.
Individualize pediatric prophylaxis dosing according to body surface area and renal function.
Monitoring & Follow-up
Monitor blood counts and renal function.
Adjust the dose in patients with renal impairment.
Risks
Boxed warnings include hematologic toxicity, impairment of fertility, fetal toxicity, mutagenesis, and carcinogenesis.
Clinically significant adverse effects include neutropenia, anemia, and thrombocytopenia.
Patient & Prescribing Data
Adults with AIDS being treated for CMV retinitis; high-risk kidney, heart, and kidney-pancreas transplant recipients receiving CMV disease prevention; and pediatric kidney or heart transplant recipients covered by reference-product labeling.
The approved generic oral solution is 50 mg/mL. High-risk transplant recipients include CMV-seronegative recipients of organs from CMV-seropositive donors. Administer with food; monitor blood counts and renal function, and adjust dosing for renal impairment.
Clinical Best Practices
Use the oral solution in adults only when they are unable to swallow tablets, according to the reference product's labeling.
Ensure the solution is prepared by a pharmacist before dispensing.
For pediatric prophylaxis, individualize dosing based on body surface area and renal function.
A modeling study projects 83% more childhood chronic hepatitis B infections and 1.8 million susceptible young adults under a shared decision-making vaccination strategy.
